Modify How Biotechnology Companies Are Analyzed
Your ratings for biotechnology companies are based largely on technical analysis. These companies burn cash before a drug is approved, and should not be valued on quarterly EPS or P/E multiples. Consider moving to DCF.
31st
ranked
Billy Slatts
shared this idea